T2DM is a progressive disease, primarily characterised by a decline in β-cell function and worsening of insulin resistance.3 T2DM causes micro-and macrovascular complications, resulting in high morbidity, mortality, and healthcare-related costs. Glycaemic, blood pressure and lipid control form the cornerstone in preventing micro-and macrovascular complications. According to Dr Mathew John and colleagues, the longer the disease progression, the more likely a patient will require injectable therapies to optimise their glycaemic control.1

Annually, an estimated 1.6 million deaths are directly attributed to diabetes.

Please sign in to read more